protocols were included in the survival analyses, comprising 48 cases including cases 2-4, 7 and 9. The probabilities of 5 years eventfree survival (pEFS) and overall survival (pOS) were calculated using the Kaplan-Meier method; groups were compared with the log rank test. There were no differences in gender distribution (P ¼ 0.343; two-tailed Fisher exact probability test), white blood cell count (P ¼ 0.803; two-sided Mann-Whitney test), or pEFS (partial 17q gains: 0.60, SE 0.22; no partial 17q gains: 0.78, SE 0.07; P ¼ 0.292) but patients with partial 17q gain were significantly older, with a median age of 6.5 years (range 3-13 years) at diagnosis compared with 3 years (range 1-16 years) for those without partial 17q gain (P ¼ 0.0128; two-sided Mann-Whitney test), and had a lower pOS (partial 17q gains: 0.60, SE 0.22; no partial 17q gains: 0.93, SE 0.04; P ¼ 0.0200). Although based on a small number of cases, this suggests that partial 17q gain is a marker for poor prognosis, in line with some previous reportsalbeit debated-of a poor outcome in i(17q)-positive high hyperdiploid childhood ALL. 2,3, 12 To ascertain whether partial 17q gains may be more common in relapsing high hyperdiploid ALL, we investigated published series of SNP array data, finding that 1/6 (17%) cases reported by Mullighan et al.
breakpoint region of the most common isochromosome, i(17q), in human neoplasia is characterized by a complex genomic architecture with large, palindromic, low-copy repeats. The karyotype 1 and molecular mutations are well-established prognostic parameters in patients with acute myeloid leukemia (AML). Molecular mutations were identified in the vast majority of patients with normal karyotype AML (NK-AML). Mutations of the nucleophosmin (NPM1) gene 2 are prognostically favorable when they occur as isolated mutations in NK-AML. FLT3-ITD (internal tandem duplications within the FLT3 gene) confer an adverse prognosis, 3 even in case of coincidence with the NPM1 mutations. [4] [5] [6] [7] Also in patients receiving allogeneic hematopoietic stem cell transplantation, occurrence of FLT3-ITD adversely affects relapse incidence and leukemia-free survival. 8 Alterations of the CEBPA gene mediate an independent favorable prognostic impact in NK-AML (at least when they occur as double mutations). Letters to the editor tandem duplications within the MLL gene (MLL-PTD) are prognostically unfavorable in NK-AML. 11 The prognostic impact of these molecular mutations was mainly explored in the subset of NK-AML, 12 but only few studies evaluated the impact on prognosis in AML patients with aberrant and prognostically intermediate karyotypes. In a previous study focusing on the NPM1 mutations, we found no difference in survival among NPM1-mutated AML patients between normal or aberrant karyotype (AK) cases. 13 However, so far the incidence and prognostic impact of these molecular mutations in AML with AKs had not been determined in a comprehensive study.
To clarify in which subset of AML patients a mutation screening for the respective molecular markers is reasonable, we investigated a large cohort of 1981 patients at diagnosis of AML. We aimed to determine the frequency of the NPM1, CEBPA, (Figure 1a ), CEBPA monoallelic (data not shown) or double mutated patients (Figure 1b ), or patients with MLL-PTD (data not shown).
Subsequently, we analyzed the prognostic impact of the respective molecular mutations within all patients from the intermediate MRC category (thus combining normal and AKs). OS was significantly longer in patients with NPM1-mutated (median 49.6 vs 18.6 months; P ¼ 0.003) or CEBPA-mutated patients (median not reached vs mOS 21.1 months; P ¼ 0.016) compared with the respective group without these mutations. Separate analysis of double and monoallelic CEBPA mutations revealed that only double CEBPA mutations were associated with a longer OS (P ¼ 0.006) as compared with monoallelic/wild-type cases, whereas cases with monoallelic mutations did not significantly differ in OS from cases with CEBPA-wild type. OS of patients with FLT3-ITD was significantly shorter as compared with FLT3-ITD-negative patients (median 13.8 vs 24.9 months; P ¼ 0.003), and MLL-PTD-positive patients had shorter OS as compared with MLL-PTD-negative patients (median 10.8 vs 23.0 months; P ¼ 0.039).
Restricting the analysis to patients with AKs within the intermediate MRC category NPM1-mutated patients revealed a trend to a longer OS compared with NPM1 wild type (median not reached vs 18 months; P ¼ 0.078). NPM1-mutated/FLT3-ITD-negative patients revealed a significantly longer OS as compared with all other combinations of NPM1 mutations and FLT3-ITD (median not reached vs 18.0 months; P ¼ 0.033; Figure 1c) , and a shorter OS for patients with FLT3-ITD as compared with FLT3-ITD-negative patients (median 5.7 vs 23.0 months; P ¼ 0.015; Figure 1d ). These results in AKs of the intermediate MRC category were corresponding to our previously published data in NK-AML, showing a clear survival benefit for the NPM1-mutated/FLT3-ITD-negative patients, whereas the survival of patients with an NPM1-mutated/FLT3-ITD-positive status did not differ significantly from the NPM1-wildtype/FLT3-ITD-positive patients. 4 Furthermore, in our cohort of AKs from the intermediate MRC category, a positive CEBPA mutation status conferred longer OS as compared with CEBPA-wild-type patients (median not reached vs 18.0 months; P ¼ 0.022). In detail, a trend to longer OS was observed for double mutations (P ¼ 0.062) as compared with monoallelic/wild-type cases, but not for monoallelic CEBPA mutations (the 10 homozygously CEBPA-mutated cases were excluded from these calculations due to the limited size of this subgroup). These results were in accordance with the previous data from the literature on AML with NK, demonstrating that only double CEBPA mutations 9 mediate an independent favorable prognostic effect. 10 In the present study, the MLL-PTD were only associated with shorter OS in the total cohort with intermediate risk karyotype and in the subset with NK, whereas an impact on OS in patients with AKs was not observed (Table 1b) .
In conclusion, MLL-PTD, FLT3-ITD and mutations in NPM1 and CEBPA are rare in the unfavorable cytogenetic subset. In the favorable cytogenetic category only FLT3-ITD are observed at a mentionable frequency in patients with t(15;17)/PML-RARA. Further, the NPM1 mutations, FLT3-ITD and CEBPA mutations were proven here for the first time to be prognostically relevant in patients with AKs from the In vitro studies indicated that MSCs have immunomodulatory activities: they inhibit T and NK cell activation, B-cell terminal differentiation and dendritic cell maturation and functions. 2 Little is known about the action of MSCs in vivo but a recent report showed that MSCs affect dendritic cell homing to lymph nodes, thus impairing T-cell priming. 3 Although there is evidence from in vivo studies that MSCs are able to reduce inflammatory damage without engraftment, 4 it is not clear whether their immunomodulatory effects rely on soluble mediators or cell-cell contacts (reviewed in Yagi et al. 2 ). There is a growing interest in using MSCs to treat human inflammatory diseases, including severe (grade III-IV) steroid resistant acute graft versus host disease (aGVHD). Various trials reported non-homogeneous results, with MSCs responses varying from 15 to 55% of treated patients. Although a study using a large cohort of patients provided encouraging results (reviewed in Tolar et al.
5
), recent data could not confirm the efficacy of MSCs for the treatment of GVHD. 6 The reasons for these conflicting results are not clear and, among others, may include differences in the number of MSCs that remain viable in patients overtime, a critical factor that so far is very difficult to control.
Another critical aspect of MSC-based cell therapy is its safety, especially when considering long-term complications: MSCs may cause tumor formation 7, 8 or aberrantly differentiate after ectopic engraftment. 9 Finally, another risk factor is associated with the administration route. Indeed, although the number of MSCs required to achieve immunomodulation in vivo is basically unknown, injection of large number of cells may be necessary to obtain maximal clinical benefit given the low rate of cell retention and survival. In these conditions, MSCs may form aggregates that could cause pulmonary emboli or infarctions in patients. 10 Considering all these issues, we decided to study the immunomodulatory effects of encapsulated mouse MSCs (E-MSCs). Indeed, this procedure would allow not only to solve all safety problems related to MSCs administration, but also to design precise protocols in which cell viability, and therefore cell dosage, is standardized. Importantly, this approach might provide conclusive data in support of either the endocrine or the paracrine/contact hypothesis for the in vivo immunomodulatory activity of MSCs.
Alginate is the most commonly employed polymer for cell microencapsulation because of its excellent biocompatibility and in vivo stability. 11 MSCs derived from B6 mice were used for the preparation of alginate microcapsules that, when analyzed by optical microscopy, showed uniform and spherical morphology (Figure 1a) , with an average diameter of 600-700 mm. Staining with fluorescein diacetate and ethidium bromide showed that the microencapsulation procedure did not affect MSCs viability, even after 7 days of in vitro incubation (Figure 1b) . In order to demonstrate that E-MSCs do not lose their multipotentiality, we compared the osteogenic and adipogenic differentiation of MSCs extracted from 7-day-old microcapsules with that of control MSCs. Both populations displayed analogous positivity for Alizarin Red staining after 15 days of conditioning with osteogenic stimuli (Supplementary Figure 1a) . Similarly, the staining with Oil Red after adipogenic stimulation showed comparable differentiation 
